A Phase I/II, Open-Label, Dose-Escalation and -Expansion, Safety, Pharmacokinetics and Efficacy Study of SHR3680 in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 30 Mar 2017
At a glance
- Drugs SHR 3680 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 10 Jun 2017 Biomarkers information updated
- 19 Apr 2016 Status changed from not yet recruiting to recruiting.
- 04 Mar 2016 New trial record